Skip to Main Content

Arena Pharmaceuticals (ARNA) is handing off one of its drug candidates to United Therapeutics (UTHR) in exchange for an eye-popping $800 million upfront payment, the company announced Thursday. The deal could ultimately be worth up to $1.2 billion.

United will receive most of the rights to ralinepag, which Arena has been testing for pulmonary arterial hypertension. The drug is currently in Phase 3 clinical trials.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.